PT83434B - Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida - Google Patents

Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida

Info

Publication number
PT83434B
PT83434B PT83434A PT8343486A PT83434B PT 83434 B PT83434 B PT 83434B PT 83434 A PT83434 A PT 83434A PT 8343486 A PT8343486 A PT 8343486A PT 83434 B PT83434 B PT 83434B
Authority
PT
Portugal
Prior art keywords
peptid
recombinant
protein
preparation
acquired immunodeficiency
Prior art date
Application number
PT83434A
Other languages
English (en)
Portuguese (pt)
Other versions
PT83434A (en
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of PT83434A publication Critical patent/PT83434A/pt
Publication of PT83434B publication Critical patent/PT83434B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT83434A 1985-09-25 1986-09-25 Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida PT83434B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (2)

Publication Number Publication Date
PT83434A PT83434A (en) 1986-10-01
PT83434B true PT83434B (pt) 1988-07-29

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
PT83434A PT83434B (pt) 1985-09-25 1986-09-25 Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida

Country Status (22)

Country Link
CN (1) CN1020752C (OSRAM)
AT (1) ATA256786A (OSRAM)
CH (1) CH676247A5 (OSRAM)
DE (1) DE3690508T1 (OSRAM)
DK (1) DK455486A (OSRAM)
ES (2) ES2002490A6 (OSRAM)
FI (1) FI863848L (OSRAM)
FR (1) FR2587720A2 (OSRAM)
GB (1) GB2181435B (OSRAM)
GR (1) GR862412B (OSRAM)
HU (1) HU205780B (OSRAM)
IE (1) IE59314B1 (OSRAM)
IL (1) IL80073A (OSRAM)
IT (1) IT1195829B (OSRAM)
MY (1) MY103182A (OSRAM)
NL (1) NL8602422A (OSRAM)
NO (1) NO863803L (OSRAM)
NZ (1) NZ217645A (OSRAM)
PT (1) PT83434B (OSRAM)
SE (4) SE8604007L (OSRAM)
WO (1) WO1987002038A1 (OSRAM)
YU (1) YU46753B (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341384C (en) * 1985-04-08 2002-08-20 Susan Mitsue Watanabe Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ES2056054T3 (es) * 1986-09-19 1994-10-01 Oncogen Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
DE3855947T2 (de) * 1987-01-16 1997-12-11 Pasteur Institut Peptide mit den immunologischen Eigenschaften von HIV-2
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
EP0343132B1 (en) * 1988-05-06 1994-08-17 Ferropas Ag Methods and systems for producing HIV antigens
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1990012880A1 (en) * 1989-04-18 1990-11-01 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
EP0431128B1 (en) * 1989-06-01 2003-03-26 Applied Biotechnology, Inc. Vector coding for self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
DK0611397T3 (da) * 1991-11-08 2002-10-07 Upjohn Co Vaccine mod katteleukæmivirus
PT679088E (pt) 1992-09-29 2002-12-31 Inhale Therapeutic Syst Administracao pulmonar de fragmentos activos de hormona paratiroide
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
BR9507023A (pt) 1994-03-07 1997-09-23 Inhale Therapeutic Syst Processos para aerossolização de uma dose de insulina para a liberação respiratória de insulina e para preparação de uma composição de insulina e composição de insulina
AU5259796A (en) * 1995-02-10 1996-08-27 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ES2143570T3 (es) * 1995-09-06 2000-05-16 Schablonentechnik Kufstein Ag Procedimiento para la fabricacion de una plantilla de serigrafia.
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (en) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
DE122005000039I1 (de) * 1984-10-18 2006-02-23 Pasteur Institut DNS-Fragmente des GAG-Gens von LAV
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
FI861626A7 (fi) * 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Also Published As

Publication number Publication date
IE862525L (en) 1987-03-25
ES2002490A6 (es) 1988-08-16
SE9102974D0 (sv) 1991-10-14
NZ217645A (en) 1991-11-26
SE9102975D0 (sv) 1991-10-14
IT8667730A0 (it) 1986-09-24
FR2587720A2 (fr) 1987-03-27
IT1195829B (it) 1988-10-27
FR2587720B2 (OSRAM) 1995-02-10
ATA256786A (de) 1995-05-15
GB2181435A (en) 1987-04-23
CN1020752C (zh) 1993-05-19
NO863803D0 (no) 1986-09-24
CH676247A5 (OSRAM) 1990-12-28
IL80073A0 (en) 1986-12-31
YU165486A (en) 1989-08-31
SE9102974L (sv) 1993-04-15
NL8602422A (nl) 1987-04-16
FI863848A7 (fi) 1987-03-26
SE9102975L (sv) 1993-04-15
WO1987002038A1 (en) 1987-04-09
IE59314B1 (en) 1994-02-09
YU46753B (sh) 1994-05-10
PT83434A (en) 1986-10-01
HU205780B (en) 1992-06-29
HUT42133A (en) 1987-06-29
ES2006941A6 (es) 1989-05-16
GB8622987D0 (en) 1986-10-29
GR862412B (en) 1987-01-23
GB2181435B (en) 1990-01-10
FI863848A0 (fi) 1986-09-24
NO863803L (no) 1987-03-26
SE8604007D0 (sv) 1986-09-23
SE9102976D0 (sv) 1991-10-14
DK455486D0 (da) 1986-09-24
SE8604007L (sv) 1987-03-26
DE3690508T1 (OSRAM) 1988-06-23
MY103182A (en) 1993-05-29
FI863848L (fi) 1987-03-26
IL80073A (en) 1995-01-24
SE9102976L (sv) 1993-04-15
CN86106632A (zh) 1987-05-13
DK455486A (da) 1987-03-26

Similar Documents

Publication Publication Date Title
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
FR2632863B2 (fr) Virus du fowlpox recombinant et vaccins derives de ces virus
FI871362L (fi) Virusvaccin.
FR2620459B1 (fr) Virus recombinant de la vaccine
FR2621487B1 (fr) Virus avipox recombinant
SI0831921T1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
ATA902590A (de) Rekombinantes pockenvirus
IL84980A (en) Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins, their preparation and use
DE3850019D1 (de) Rekombinantes Avipoxvirus.
DE3650289D1 (de) Spike-protein des virus der infektiösen bronchitis.
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
BR8606969A (pt) Perfluoropolieteres e processo de preparacao dos mesmos e de oxido de perfluoropolimetileno
DE10399004I2 (de) Klonierung und expression von Wirtssch}tzenden immunogenen des Infektioesen Bursavirus (ibdv).
FI885237A7 (fi) Menetelmä yhdistelmä-E. colissa ilmennetyn P. falciparum-CS-proteiinir okotteen eristämiseksi ja puhdistamiseksi
DK476688D0 (da) Hiv-proteiner og -peptider, der er nyttige ved aids-diagnose, -profylakse og -terapi
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
NO964874L (no) Fusjonsglykoprotein fra HCMV og HSV
EE9400068A (et) Ravimsegud viirushepatiidi B (HBV) infektsiooni ja selle poolt p6hjustatud haiguste raviks ja nende valmistamise protsess
DK720588A (da) Forbindelser til anvendelse ved behandling eller forebyggelse af human-immundefektvirus-(hiv)-infektion, og farmaceutiske praeparater indeholdende samme
ES8800358A1 (es) Un procedimiento para preparar un polipeptido hibrido.
DE3853672D1 (de) Nichtzurückschlagende RNS-Viren.
FI891917A7 (fi) HIV:n rekombinantti-GAG-prekursori, tuote, menetelmä ja käyttö AIDS-rokotteena
DK219187A (da) Rekombinant-virus

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19970731